Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
VANCOUVER, British Columbia, March 29, 2017 -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, President & CEO, will provide a corporate update at the upcoming 16th Annual Needham Healthcare Conference in New York on Wednesday, April 5th 2017.
Aquinox Presentation Details:
Date: Wednesday, April 5th 2017
Time: 1:40 pm Eastern Time / 10:40 am Pacific Time
Location: New York, NY – Westin New York Grand Central
A live audio webcast and archive of the event will be available at:
http://wsw.com/webcast/needham80/aqxp
To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a late clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Our primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1, or SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. In September 2016, we began enrolling patients in a Phase 3 clinical trial of AQX-1125 in our lead indication, Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). Other indications are under consideration for future investigation. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit www.aqxpharma.com.
Investor Contact Info:
Brendan Payne
Associate Director, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.901.3019
[email protected]
Gitanjali Ogawa
Vice President
The Trout Group
646-378-2949
[email protected]
